Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Trial

[1]  Y. Hosomi,et al.  Erlotinib with or without bevacizumab as a first‐line therapy for patients with advanced nonsquamous epidermal growth factor receptor‐positive non‐small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 study , 2022, Thoracic cancer.

[2]  U. Dafni,et al.  Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC—a systematic review and meta-analysis , 2022, ESMO open.

[3]  K. Azuma,et al.  Randomized phase II study of osimertinib plus bevacizumab versus osimertinib for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations; WJOG9717L study. , 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  Jiong Cai,et al.  Potential benefit of osismertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer , 2022, Journal of Translational Medicine.

[5]  U. Dafni,et al.  A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Ying Chen,et al.  Concurrent Blockade of Endothelial EGFR and VEGF Signaling on Malignant Associated Pleural Fluid Induced Angiogenesis: From Clinic to Bench , 2021, Biomedicines.

[7]  Dong-Wan Kim,et al.  Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma , 2021, Translational lung cancer research.

[8]  Ying Cheng,et al.  Bevacizumab Plus Erlotinib in Chinese Patients with Untreated, EGFR-Mutated, Advanced NSCLC (ARTEMIS-CTONG1509): A Multicenter Phase 3 Study , 2020 .

[9]  Cheng-Bo Han,et al.  Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review , 2020, Frontiers in Oncology.

[10]  T. Yamanaka,et al.  Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study. , 2020, Lung cancer.

[11]  Long Huang,et al.  Osimertinib combined with bevacizumab for leptomeningeal metastasis from EGFR‐mutation non‐small cell lung cancer: A phase II single‐arm prospective clinical trial , 2020, Thoracic cancer.

[12]  B. Chang,et al.  High PD-L1 Expression is Associated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy , 2020, OncoTargets and therapy.

[13]  Julie L. Yang,et al.  Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial. , 2020, JAMA oncology.

[14]  Y. Shao,et al.  Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non–Small Cell Lung Cancer , 2020, Frontiers in Oncology.

[15]  Versione,et al.  Common Terminology Criteria for Adverse Events , 2020, Definitions.

[16]  J. Shih,et al.  Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[17]  N. Girard,et al.  Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study. , 2019, Lung cancer.

[18]  E. Giovannetti,et al.  Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer , 2019, British Journal of Cancer.

[19]  S. Morita,et al.  Phase I/II Study of Osimertinib With Bevacizumab in EGFR-mutated, T790M-positive Patients With Progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L). , 2019, Clinical lung cancer.

[20]  A. Gemma,et al.  Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. , 2019, The Lancet. Oncology.

[21]  Nikolaus Schultz,et al.  Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers , 2018, Clinical Cancer Research.

[22]  Ying Cheng,et al.  Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[23]  Chia-Chi Lin,et al.  Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Ahn,et al.  Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer , 2017, The New England journal of medicine.

[25]  T. Mitsudomi,et al.  Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. , 2016, The Lancet. Oncology.

[26]  K. Goto,et al.  Erlotinib for Japanese patients with activating EGFR mutation-positive non-small-cell lung cancer: combined analyses from two Phase II studies. , 2016, Future oncology.

[27]  V. Aidinis,et al.  Mast cells mediate malignant pleural effusion formation. , 2015, The Journal of clinical investigation.

[28]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[29]  S. Thongprasert,et al.  A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER) , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[30]  R. McCormack,et al.  First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study , 2013, British Journal of Cancer.

[31]  W. Olszewski,et al.  EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidence. , 2013, International journal of clinical and experimental pathology.

[32]  A. Mansfield,et al.  The Role of Vascular Endothelial Growth Factor in the Pathogenesis, Diagnosis and Treatment of Malignant Pleural Effusion , 2013, Current Oncology Reports.

[33]  Gillian Ellison,et al.  EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples , 2012, Journal of Clinical Pathology.

[34]  N. Ridgway,et al.  Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. , 2011, Journal of thoracic disease.

[35]  G. Giaccone,et al.  American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  M. Ladanyi,et al.  Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  D. Moher,et al.  CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials , 2010, PLoS medicine.

[38]  D. Moher,et al.  CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials , 2010, Journal of pharmacology & pharmacotherapeutics.

[39]  P. Jänne,et al.  Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance , 2009, Clinical Cancer Research.

[40]  O. Miettinen.  Survival analysis: up from Kaplan–Meier–Greenwood , 2008, European Journal of Epidemiology.

[41]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[42]  Lin Huan,et al.  Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer , 2010 .

[43]  N. Siafakas,et al.  The angiogenetic pathway in malignant pleural effusions: Pathogenetic and therapeutic implications. , 2010, Experimental and therapeutic medicine.

[44]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.